Digestive Diseases and Sciences

, Volume 52, Issue 3, pp 753–759 | Cite as

Usefulness of MMP-9/TIMP-1 in Predicting Tumor Recurrence in Patients Undergoing Curative Surgical Resection for Gastric Carcinoma

  • Yeon Seok Seo
  • Jong-Jae Park
  • Ji Hoon Kim
  • Jin Yong Kim
  • Jong Eun Yeon
  • Jae Seon Kim
  • Kwan Soo Byun
  • Young-Tae Bak
Original Article
First Online:
Received:
Accepted:

Abstract

Degradation of the extracellular matrix is an essential step in tumor invasion and metastasis. It involves the actions of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). We evaluated the expression of MMP-9 and TIMP-1 in gastric carcinomas and the relationship between this expression and tumor recurrence. Eighty patients who had undergone curative surgical resection for gastric carcinoma were included. Resected gastric tissue samples were stained immunohistochemically to evaluate the expression of MMP-9 and TIMP-1. TIMP-1 expression was related to the depth of tumor invasion and lymph node metastasis. The proportion of tumors larger than 5 cm, or displaying muscle layer invasion, and the cumulative incidence of tumor recurrence were significantly elevated in patients with tumors expressing TIMP-1. Furthermore, these measures were lowest in patients with no TIMP-1 expression and highest in patients who only expressed TIMP-1. In conclusion, TIMP-1 expression and the balance between expression of MMP-9 and expression of TIMP-1 may be important indicators of tumor progression and predictors of tumor recurrence.

Keywords

Gastric cancer Neoplasm recurrence Matrix metalloproteinases Tissue inhibitor of metalloproteinases 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics, 1997. CA Cancer J Cli 47:5–27Google Scholar
  2. 2.
    Samson PS, Escovidal LA, Yrastorza SG, Veneracion RG, Nerves MY (2002) Re-study of gastric cancer: analysis of outcome. World J Surg 26:428–433PubMedCrossRefGoogle Scholar
  3. 3.
    Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H (1999) Extended lymph node dissection for gastric cancer. N Engl J Med 340:908–914PubMedCrossRefGoogle Scholar
  4. 4.
    Hart IR, Saini A (1992) Biology of tumour metastasis. Lancet 339:1453–1457PubMedCrossRefGoogle Scholar
  5. 5.
    Kohn EC, Liotta LA (1995) Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55:1856–1862PubMedGoogle Scholar
  6. 6.
    Urbanski SJ, Edwards DR, Hershfield N, Huchcroft SA, Shaffer E, Sutherland L, Kossakowska AE (1993) Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn Mol Pathol 2:81–89PubMedGoogle Scholar
  7. 7.
    Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr (1993) Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434–1441PubMedGoogle Scholar
  8. 8.
    Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365–5369PubMedGoogle Scholar
  9. 9.
    Boag AH, Young ID (1994) Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 144:585–591PubMedGoogle Scholar
  10. 10.
    Muller D, Wolf C, Abecassis J, et al. (1993) Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 53:165–169PubMedGoogle Scholar
  11. 11.
    Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMedGoogle Scholar
  12. 12.
    Tsuchiya Y, Sato H, Endo Y, Okada Y, Mai M, Sasaki T, Seiki M (1993) Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res 53:1397–1402PubMedGoogle Scholar
  13. 13.
    Douglas DA, Shi YE, Sang QA (1997) Computational sequence analysis of the tissue inhibitor of metalloproteinase family. J Protein Chem 16:237–255PubMedCrossRefGoogle Scholar
  14. 14.
    Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H (2005) Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8:86–94PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang S, Li L, Lin JY, Lin H (2003) Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 9:899–904PubMedGoogle Scholar
  16. 16.
    Green FL PD FI, Fritz A, Balch CM, et al. (2002) AJCC cancer staging manual, 6th ed., pp 131–139Google Scholar
  17. 17.
    Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K (2000) Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res 6:3581–3854PubMedGoogle Scholar
  18. 18.
    Torii A, Kodera Y, Uesaka K, Hirai T, Yasui K, Morimoto T, Yamamura Y, Kato T, Hayakawa T, Fujimoto N, Kito T (1997) Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 84:133–136PubMedCrossRefGoogle Scholar
  19. 19.
    Yoshikawa T, Saitoh M, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y (1999) Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer 86:1929–1935PubMedCrossRefGoogle Scholar
  20. 20.
    Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y (2000) Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer. Cancer Lett 151:81–86PubMedCrossRefGoogle Scholar
  21. 21.
    Joo YE, Seo YH, Lee WS, Kim HS, Choi SK, Rew JS, Park CS, Kim SJ (2000) Expression of tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma. Korean J Intern Med 15:171–178PubMedGoogle Scholar
  22. 22.
    Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298:29–32PubMedCrossRefGoogle Scholar
  23. 23.
    Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, Abe R, Ueo H, Akiyoshi T (1997) Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76:531–536PubMedGoogle Scholar
  24. 24.
    Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, Seiki M (1992) Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 7:77–83PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Yeon Seok Seo
    • 1
  • Jong-Jae Park
    • 1
    • 3
  • Ji Hoon Kim
    • 1
  • Jin Yong Kim
    • 2
  • Jong Eun Yeon
    • 1
  • Jae Seon Kim
    • 1
  • Kwan Soo Byun
    • 1
  • Young-Tae Bak
    • 1
  1. 1.Department of Internal MedicineKorea University Medical Center, Guro HospitalSeoulKorea
  2. 2.Department of Internal MedicineSungkyunkwan University School of MedicineSeoulKorea
  3. 3.SeoulKorea

Personalised recommendations